domperidone has been researched along with Multiple Sclerosis, Chronic Progressive in 2 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Multiple Sclerosis, Chronic Progressive: A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Domperidone treatment was reasonably well tolerated, but adverse events occurred in 84% and serious adverse events in 15% of patients." | 3.01 | Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial. ( Cerchiaro, G; Cutter, GR; Kaur, S; Kim, J; Koch, MW; Metz, LM; Sage, K; Yong, VW, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, MW | 1 |
| Sage, K | 1 |
| Kaur, S | 1 |
| Kim, J | 1 |
| Cerchiaro, G | 1 |
| Yong, VW | 1 |
| Cutter, GR | 1 |
| Metz, LM | 1 |
| Fox, RJ | 1 |
| Kryscio, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)[NCT02308137] | Phase 2 | 64 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for domperidone and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
Topics: Adult; Domperidone; Dopamine Antagonists; Drug Repositioning; Female; Humans; Male; Medical Futility | 2021 |
1 other study available for domperidone and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
Topics: Domperidone; Humans; Medical Futility; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2021 |